Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

oleh: J. Van Wyk, F. Ajana, F. Bisshop, S. De Wit, Y. Osiyemi, J. Portilla, J. Routy, C. Wyen, M. Ait-Khaled, M. Nascimento, K. Pappa, R. Wang, J. Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, K. Smith, Y. El-Bahy